Sugi Predict

Sugi Predict / Compounds / SCHEMBL3490673

SCHEMBL3490673

SCHEMBL3490673

NC(=O)C1(C(=O)N(c2ccc(F)cc2)c2cc(Oc3nccc(-c4cn[nH]c4)n3)ccc2F)CC1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.39
▸ AXL P30530 2/20 0.37
▸ MAPK14 Q16539 11/20 0.35
▸ PDE10A Q9Y233 2/20 0.35
▸ RXRA P19793 1/20 0.34
▸ GRIN1 Q05586 1/20 0.34
▸ GRIN2B Q13224 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ FGFR1 P11362 1/20 0.32
▸ FGFR2 P21802 1/20 0.32
▸ FGFR3 P22607 1/20 0.32
▸ ROCK1 Q13464 1/20 0.32
▸ MET P08581 1/20 0.32
▸ MERTK Q12866 1/20 0.32
▸ BRD4 O60885 1/20 0.32
▸ BRDT Q58F21 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2449860 0.88 AXL (0.36) AXLMAPK14PDE10ARXRAGRIN1
SCHEMBL2447423 0.87 CSF1R (0.40) MAPTL3MBTL1AXLPDE10AFGFR1
SCHEMBL2413900 0.79 AXL (0.45) AXLROCK1METMERTK
SCHEMBL28750187 0.78 FGFR1 (0.44) AXLFGFR1FGFR2FGFR3
SCHEMBL2409748 0.75 CSF1R (0.39) AXLMET
SCHEMBL3490670 0.75 AXL (0.54) AXLFGFR1METMERTK
SCHEMBL19987750 0.73 AXL (0.43) AXLFGFR1METMERTK
SCHEMBL29729024 0.73 AXL (0.43) AXLFGFR1METMERTK
SCHEMBL139146 0.72 MET (0.41) AXLMAPK14FGFR1METMERTK
SCHEMBL3492687 0.72 SCN9A (0.33) AXLMAPK14FGFR1METMERTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2365752-B1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS LLC (US) 2014-09-24 — — EP disclosed
US-8486951-B2 Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2013-07-16 — — US disclosed
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2013-03-28 — — US disclosed
US-8278331-B2 N-acyl ureas exhibiting anti-cancer and anti-proliferative activities DECIPHERA PHARMACEUTICALS, LLC (US) 2012-10-02 — — US disclosed
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES DECIPHERA PHARMACEUTICALS, LLC 2010-05-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079362-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB MAPT 3045/4885L3MBTL1 1617/4885AXL 439/4885
US-20100120806-A1 CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES KIT, PDGFRA, PDGFRB MAPT 3019/4885L3MBTL1 1763/4885AXL 441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.